

GJB4 promotes gastric cancer cell proliferation and migration via Wnt/CTNNB1 pathway

This article was published in the following Dove Press journal:
OncoTargets and Therapy

GuiYuan Liu¹
Yi Pang¹
Yajun Zhang²
HaiRong Fu¹
Wei Xiong¹
YongHui Zhang¹

¹Chongqing Engineering Research Center of Antitumor Natural Drugs, Chongqing Three Gorges Medical College, Chongqing 404120, People's Republic of China; ²Chongqing Engineering Laboratory of Targeted and Innovative Therapeutics, Chongqing Key Laboratory of Kinase Modulators as Innovative Medicine, IATTI, Chongqing University of Arts and Sciences, Chongqing 402160, People's Republic of China

Background: Gap junction beta-4 protein (GJB4), or connexin 30.3, a member of integral membrane proteins, has been shown to involve and may function as a tumor promoter in tumorigenesis. However, the role of GJB4 in gastric cancer (GC) is still unclear.

Materials and methods: We used Progression-free survival Kaplan-Meier analysis and Western blot analysis to detect the expression of GJB4 in GC tissues and cells. In addition, both in vitro and in vivo assays were used to determine the effect of GJB4 on malignant behavior in GC cells.

Results: We found that GJB4 was overexpressed in gastric cancer tissues and cells compared with normal tissues and cells. The high GJB4 expression was significantly associated with poor overall survival of GC patients. Knocking down GJB4 in GC cells significantly suppressed cell proliferation and migration. We found that the effects of GJB4-knockdown on GC cells were associated with downregulation of CTNNB1 and its downstream MYC, MMP7 and CCND1 expression. In addition, we found that the promotive effect of GJB4 overexpression on cell proliferation and migration was negated by XAV-939, which is the inhibitor of Wnt/CTNNB1 pathway. Therefore, we revealed a novel mechanism by which GJB4 could activate the Wnt/CTNNB1 pathway to promote GC cell's proliferation and migration.

Conclusion: This study offer insights into GJB4 function and indicate that GJB4 is a promising biomarker and therapeutic target for gastric cancer patients.

Keywords: GJB4, cell proliferation, migration, gastric cancer, CTNNB1

Introduction

Gastric cancer (GC) is the most gastrointestinal malignancy and the second most common cause of cancer-related death worldwide, with an estimated 700,000 mortalities annually worldwide.¹⁻³ Various factors contribute to the pathogenesis of GC, including the genetic background of patients and environment factors.⁴ Despite great advances in the diagnosis and therapy of patients with GC, the prognosis of GC patients remains poor with a 6-month survival rate of <15%.⁵ Therefore, it is of great urgent to explore the molecular mechanisms underlying gastric cancer progression and develop novel therapeutic targets for improving the treatment for GC patients.

Gap junctions are transmembrane channels, which mediate the transfer of small molecules between the cytoplasm of neighbouring cells.⁶ Gap junctions play an important role in cell cycle, cell differentiation, migration and invasion by regulation of signal transduction.⁷⁻¹⁰ They are formed by proteins named connexins, which are homologous four-transmembrane-domain proteins, belong to a family of 21

Correspondence: YongHui Zhang
Chongqing Engineering Research Center of Antitumor Natural Drugs, Chongqing Three Gorges Medical College, 366 Tianxing Road, Wan Zhou, Chongqing 404120, People's Republic of China
Tel +1 858 095 1210
Email 304947859@qq.com

isotypes in human cells.¹¹ Among these isotypes, the amino acid sequences of transmembrane domains are highly conserved, whereas the intracellular carboxyl-terminal regions are highly variable.^{12,13} GJA1 (connexin 43) and GJB2 (connexin 26) are the two of the most studied gap junction protein, have been shown to be expressed at higher levels in tumors.^{14,15} High levels of GJA1 and GJB2 are reported to be associated with cell migration, invasion, and poor prognosis. In addition, GJA1 could also confer the chemoresistance of glioblastoma cells to temozolomide via activating pro-survival pathway.^{16,17}

Gap junction beta-4 protein (GJB4), or connexin 30.3, has been recently reported that could promote metastasis and chemoresistance via Src activation in lung cancer.¹⁸ However, the expression profile and biological function of GJB4 in GC remains largely unidentified.

In this study, we demonstrated that GJB4 was commonly expressed in GC cells. We found that downregulation of GJB4 efficiently suppressed cell proliferation, migration and tumorigenesis by regulating the Wnt/CTNNB1 pathway in GC cells. These data offer insights into GJB4 function and indicate that GJB4 as a potential target for GC patients.

Materials and methods

Cell culture and transfection

Human normal gastric mucosa epithelial cells GES-1, gastric cancer cell lines (MKN-45, SGC-7901, BGC-823 and HGC-27) and a retroviral packaging cell line (293FT) were purchased from the American Type Culture Collection (ATCC) (USA) and cultured as previously described.¹⁹ GJB4-specific short hairpin RNA (shGJB4) and GFP-specific short hairpin RNA (shGFP) were purchased from GenePharma Co., Ltd (Shanghai, China), and cloned into the pLKO.1 vector. Sequences of the shGJB4 are given in Table 1. Vector encoding of human GJB4 were constructed by PCR-based amplification and subsequently subcloned into the pCDH-CMV-MCS-EF1-copGFP vector. Sequences of the primers used are given in Table 2. Lentivirus was produced as previously described.¹⁹

Table 1 Sequence of GJB4-specific shRNA

shGJB4-1-F	CCGGTGTATATGGCAACAGTATATGCTCGAGCATATACTGTTGCCATATACATTTTTG
shGJB4-1-R	AATTCAAAAATGTATATGGCAACAGTATATGCTCGAGCATATACTGTTGCCATATACA
shGJB4-2-F	CCGGCCACACTGTGGACTGTTACATCTCGAGATGTAACAGTCCACAGTGTGGTTTTTG
shGJB4-2-R	AATTCAAAAACCACTGTGGACTGTTACATCTCGAGATGTAACAGTCCACAGTGTGG

Abbreviations: shGJB4, short hairpin-Gap junction beta-4.

Cell proliferation analysis

Cell viability was assessed using the MTT assay. Cells (1×10^3 wells) were seeded into 96-well plates, and then were detected at the point from day 0 to 6. All experiments were carried out independently in triplicate.

BrdU incorporation assay

Cells (2×10^4 cells/well) were seeded on coverslips in 24-well plates and incubated overnight. After treatment with 10 μ g/ml BrdU (Sigma) for 30 min, cells were incubated sequentially with primary antibody against BrdU overnight and appropriate secondary antibody for 2 hrs. DAPI was added for nuclear staining. BrdU positive cells were observed and calculated from microscopy fields (Nikon 80i, Nikon Corporation, Tokyo, Japan).

Flow cytometry

For cell cycle analysis, cells were harvested and then fixed in 75% ethanol at 4°C for 24 h, and then incubated with propidium iodide (PI) and RNaseA at 37°C for 30 min.

Cells were examined by flow cytometry (BD Biosciences, San Jose, CA, USA) and analyzed by FlowJo software (version FlowJo 7.6; FlowJo LLC, Ashland, OR, USA).

Immunofluorescent analysis

Cells (1×10^4 cells/well) were grown on coverslips. After incubation with 4% paraformaldehyde for 20 min and 0.25% Triton X-100 for 15 min, the cells were incubated sequentially with primary antibody against MKI67 (Abcam) or PCNA (Abcam) overnight and appropriate secondary antibody for 2 hrs. Cell nuclei were stained with DAPI for 30 min. Cells were imaged and calculated from randomly chosen microscopic fields at X20 magnification (Nikon 80i; Nikon Corp.).

Transwell assay

24-well Boyden chambers (8 μ m pore size, Corning) were used in the Transwell assay. Medium with 10% FBS as a chemoattractant was added to the lower chamber, and cells with serum-free media were placed in the upper chamber.

Table 2 Primer pairs for real-time PCR

Gene	Sequence (5'-3')
GJB4-F	TCCCTGTACGACAACCTGAG
GJB4-R	CGGTGGAAGATATAGAGGAAGCC
c-Myc-F	GTCAAGAGGCGAACACACAAC
c-Myc-R	TTGGACGGACAGGATGTATGC
MMP7-F	GAGTGAGCTACAGTGGGAACA
MMP7-R	CTATGACGCGGGAGTTTAACAT
CyclinD1-F	GCTGCGAAGTGGAAACCATC
CyclinD1-R	CCTCCTTCTGCACACATTTGAA
GAPDH-F	GGAGCGAGATCCCTCCAAAAT
GAPDH-R	GGCTGTTGTCATACTTCTCATGG

Abbreviations: GJB4, gap junction beta-4; RT-PCR, real time-polymerase chain reaction; c-MYC, MYC proto-oncogene; CyclinD1, G1/S-specific cyclin-D1; MMP7, matrix metalloproteinase-7; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Cells were fixed in 4% paraformaldehyde (PFA) and then stained with crystal violet. Cells were imaged and calculated from randomly chosen microscopy fields (Nikon 80i, Nikon Corporation, Tokyo, Japan).

Wound healing assay

For the wound healing assay, cells were seeded in 6-well plates and allowed to grow to full confluence. Wounds were made using 10- μ l pipette tip, and the wound healing process was monitored under a microscope.

Western blot

Western blotting was performed as previously described.¹⁹ The primary and conjugated secondary antibodies used are as follows: GJB4 (Abcam), CTNNB1 (Abcam), CCND1 (CST), MMP7 (CST), MYC (Abcam), GAPDH (Proteintech).

Quantitative real-time PCR

Total RNA was extracted from gastric cell lines using TRIzol Reagent (Invitrogen) and then reverse transcribed into cDNA for each sample. The expression of mRNA was defined based on Cq, and the individual values were normalized to that of the GAPDH control. All primer pairs were shown in Table 3.

Colony formation assay

To evaluate colony-forming ability, human gastric cancer cell lines (HGC-27 and SGC-7901) cells (1×10^3 wells)

Table 3 Primers pairs for human full-length GJB4

GJB4-F	ATGAACTGGGCATTTCTGC
GJB4-R	TTATGGATACCCACCTGCAT

Abbreviation: GJB4, gap junction beta-4.

stably transfected with shGFP and shGJB4 respectively were plated six-well plates with RPMI-1640 medium and 10% FBS for growth analysis. After culturing for 10 days, cells were fixed, stained with 0.1% crystal violet, and imaged and calculated in each well.

Xenograft assay

4-week-old Female NOD/SCID mice were purchased and housed in SPF room that was maintained at a constant temperature and humidity. Human gastric cancer cell lines (SGC-7901) cells (1×10^6 cells) stably transfected with shGFP and shGJB4 respectively were injected subcutaneously into the right flanks of 4-week-old Female NOD/SCID mice (6 mice/group). The tumors volumes were calculated daily based on caliper measurements of the tumor length and width. After 21 days of tumor growth, the mice were sacrificed by CO₂ inhalation, and the tumors were excised and measured. All studies were approved by the Animal Care and Use Committee of Chongqing Three Gorges Medical College, and carried out in conformity to the Guide for the Care and Use of Laboratory Animals (Ministry of Science and Technology of China, 2006).

Statistical analysis

All experiments were carried out at least three replicates. Statistical analysis was performed by Graph Pad Prism 5 system and the quantitative data were expressed as mean \pm SD. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and a value of $p < 0.05$ was considered statistically significant.

Results

GJB4 is markedly upregulated in GC and is a prognostic indicator of patients with GC

To explore whether GJB4 could be a prognostic marker for GC, We performed a data analysis of public data sets, which indicated that GJB4 expression in GC tissues was higher than that in normal stomach tissues (Figure 1A and B). Moreover, the clinical significance of GJB4 expression was further evaluated by a Progression-free survival Kaplan-Meier analysis, which demonstrated that high expression of GJB4 was significantly associated with poor overall survival in patients with GC (Figure 1C). In addition, the Lauren classification divides gastric adenocarcinoma into intestinal, diffuse and mixed types on the basis of histology. Our analysis demonstrated that high GJB4 expression was also a poor prognostic factor in intestinal, disuse and mixed Lauren types GC (Figure 1D, E and Figure S1). To further explore the expression of GJB4 in




Figure 1 GJB4 is markedly upregulated in GC and is a prognostic indicator of patients with GC.

Notes: (A, B) Box plots of GJB4 expression levels in GC patients. GJB4 expression levels were downloaded from public data sets (Deng Gastric and Cho Gastric from Oncomine). (C) Kaplan-Meier overall survival for GJB4 expression in all Lauren types gastric cancer tumours (KM plotter gastric cancer dataset). (D, E) Kaplan-Meier overall survival for GJB4 expression in intestinal and diffuse Lauren types gastric cancer tumours (KM plotter gastric cancer dataset). (F) Western blot analyses were performed to detect GJB4 expression in human gastric epithelial cell lines (GES-1) and four GC cell lines (HGC-27, SGC-7901, MKN-45, BGC-823). GAPDH served as endogenous and loading control.

Abbreviations: GC, gastric cancer; GJB4, gap junction beta-4.

GC, we detected GJB4 expression at the protein level in human gastric epithelial cell lines (GES-1) and four GC cell lines (HGC-27, SGC-7901, MKN-45, BGC-823). Compared with GES-1 cells, GJB4 expression was significantly increased in all four GC cell lines (Figure 1F). Taken together, we found that GJB4 was overexpressed in GC tissues and cell lines, and high GJB4 expression was associated with the poor prognosis of patients with GC.

GJB4 knockdown suppresses cell proliferation in GC cells

To investigate the function of GJB4 in GC cells, two shRNA sequences were used to knockdown GJB4 in HGC-27 and SGC-7901 cells, shGFP as a control (Figure 2A and B).

MTT assays showed that knockdown GJB4 significantly inhibited the growth of HGC-27 and SGC-7901 cells (Figure 2C and D). In addition, we performed BrdU, MKI67 and PCNA staining and found that the positive cells were significantly reduced after GJB4 knockdown (Figure 2E, F and Figure S2). Flow cytometry was performed to corroborate the data of proliferation, and the results showed that GJB4 knockdown led to cell cycle arrest at the G1 phase (Figure 2G and H).

GJB4 knockdown inhibits cell migration in GC cells

To determine whether GJB4 was related to the migration of GC cells, we performed Transwell assays. Then, the results




Figure 2 GJB4 knockdown suppresses cell proliferation in GC cells.

Notes: (A, B) The expression of GJB4 mRNA (upper) and protein (lower) in GJB4 knockdown HGC-27 and SGC-7901 cell lines and negative controls were detected by RT-PCR and Western blot analysis. GAPDH served as endogenous and loading control. (C, D) GC cell proliferation was measured by MTT assay. (E, F) BrdU incorporation assay was performed to examine the percentage of cells in S-phase. (G, H) Flow cytometric analysis of cell cycle distribution in HGC-27 and SGC-7901 cell lines. All data are shown as the means \pm SD, * P <0.05, ** P <0.01, *** P <0.001. All p -values are based on control versus treatment.

Abbreviations: GC, gastric cancer; GJB4, gap junction beta-4; MTT, 3-(4, 5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; BrdU, 5-Bromo-2-deoxyUridine.

showed that GJB4 knockdown significantly inhibited cell migration compared to controls (Figure 3A and B). In addition, wound healing assays demonstrated that the migratory ability was decreased in GJB4-knockdown cells (Figure 3C and D). These data indicated that downregulation of GJB4 significantly inhibited cell migration of GC cells.

GJB4 mediates cell proliferation and migration by regulating Wnt/CTNNB1 pathway

Wnt/CTNNB1 plays a key role in cell proliferation and migration in GC cells. To identify whether GJB4 influences the Wnt/CTNNB1 pathway, we performed the RT-PCR and Western blot analysis to examine the expression of CTNNB1 and its downstream molecule (MYC, MMP7 and CCND1) in GJB4-knockdown cells and control cells. We found that downregulation of GJB4 in the HGC-27 and SGC-7901 cells significantly reduced the mRNA and protein expression levels of CTNNB1, MYC, MMP7 and CCND1 (Figure 4A and B). XAV-939 is a potent Wnt/CTNNB1 inhibitor that inhibits proliferation and metastasis of cancer cells. To confirm whether the effects of GJB4 on GC cells were Wnt/CTNNB1 dependent, we treated GJB4 overexpression GC cells (HGC-27 and SGC-7901 cells) and their controls cells

with XAV-939. The accelerative effects of GJB4 on cell proliferation and migration were significantly blocked after XAV-939 treatment (Figure 4C, D and Figure S3A). In addition, Western blot analysis demonstrated that the protein levels of CTNNB1 and its downstream molecule (MYC, MMP7 and CCND1) were dramatically increased by GJB4 overexpression and were reduced by XAV-939 treatment (Figure 4E and F). Collectively, these results provided evidence that GJB4 mediates cell proliferation and migration by regulating Wnt/CTNNB1 pathway.

GJB4 knockdown inhibits self-renewal and tumor growth of GC cells

To explore the effects of GJB4 expression on colony formation of GC cells in vitro, colony formation assay was performed. As shown in Figure 5A and B, the colonies were smaller and fewer in GJB4-knockdown HGC-27 and SGC-7901 cells compared with the controls. In addition, the xenograft tumor growth assay was performed to elucidate the effect of GJB4 on GC growth in vivo. The results showed that GJB4-knockdown tumors were smaller than the controls in appearance, weight and volume (Figure 5C and D). Next, Western blot analysis showed that the protein level of GJB4, CTNNB1 and its




Figure 3 GJB4 knockdown inhibits cell migration in GC cells.

Notes: (A, B) Transwell assay was performed in GJB4-knockdown HGC-27 and SGC-7901 cell lines and negative controls. (C, D) Wound healing assay was performed in GJB4-knockdown cells. All data are shown as the means \pm SD, * P <0.05, ** P <0.01, *** P <0.001. All p -values are based on control versus treatment.

Abbreviations: GC, gastric cancer; GJB4, gap junction beta-4.

downstream gene were significantly changed in GJB4-knockdown tumors (Figure 5E). Taken together, these in vitro and in vivo results indicated that GJB4 potently promotes the tumor growth of GC cells.

Discussion

GC has long been great threats to human society, causing both patient sufferings and economic burdens. According to the latest global cancer statistics, in 2018, there will be 1.03 million new patients with GC worldwide.^{20,21} Although advances in multimodal therapy involving surgical and medical management, the mortality rates of GC patients remain high.²² Molecular-targeted therapy has become a promising treatment in cancer therapy, especially for GC.²³ Therefore, suitable molecular-targeted drugs are urgently needed for combating GC. Gap junction proteins are a family of transmembrane proteins that directly link the intercellular communication of neighboring cells by facilitating the transfer of ions and small molecules.^{24,25} Abnormal expression of Gap junction proteins and loss of Gap junctional intercellular communication (GJIC) function were associated with the disease progression of numerous pathologies, including cancer.^{26–29} The levels of different Gap junction proteins were significantly associated with degree of tumor

malignancy.³⁰ Recent studies have reported that the expression of GJB4, connexin30.3, was significantly upregulated in lung cancer cells. GJB4 promoted metastasis and enhanced chemoresistance of cancer cells by activating Src pathway. However, the biological function and molecular mechanism of GJB4 in GC have not been elucidated, especially in regards to the cell proliferation and migration of GC cells.

In the present study, we found that GJB4 was highly expressed in human GC and that GJB4 expression was positively associated with the survival probability of patients with GC. As to the biological study, we observed that downregulation of GJB4 significantly inhibited cell proliferation and migration in HGC-27 and SGC-7901 GC cells. Furthermore, GJB4 downregulation also inhibited self-renewal and tumor growth of GC cells. These results indicated that GJB4 was required for the growth and migration of GC cells.

GJB4 has been shown to modulate Src signaling in lung cancer cells. However, the molecular mechanisms of GJB4 in carcinogenesis and tumor progression remain largely unknown. Our study demonstrated that GJB4 silencing regulated the expression of various genes involved in cell proliferation and migration, such as MYC, MMP7 and CCND1, all of which are downstream molecules of the Wnt/CTNBN1 signaling. We found that GJB4 knockdown




Figure 4 GJB4 mediates cell proliferation and migration by regulating Wnt/CTNNB1 pathway.

Notes: (A, B) Relative mRNA and protein expression of CTNNB1 and its downstream genes (MYC, MMP7 and CCND1) in GJB4 knockdown or control HGC-27 cells and SGC-7901 cells was detected by RT-PCR and Western blot analysis. (C, D) Cell proliferation of indicated stable cell lines was measured by MTT assay. (E) Cell migration of indicated stable cell lines was measured by Transwell assay. (F, G) Protein expression levels of GJB4, CTNNB1, MYC, MMP7 and CCND1 were analyzed by Western blot analysis. All data are shown as the means \pm SD, * P <0.05, ** P <0.01, *** P <0.001. All p -values are based on control versus treatment.

Abbreviations: GC, gastric cancer; GJB4, gap junction beta-4; RT-PCR, real time-polymerase chain reaction; MYC, MYC proto-oncogene; CCND1, G1/S-specific cyclin-D1; MMP7, matrix metalloproteinase-7; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide.

was associated with the suppression of CTNNB1 expression level in GC cells. Furthermore, the promotive effect of GJB4 overexpression on cell proliferation and

migration was blocked by treatment with Wnt/CTNNB1 inhibitor XAV-939. Therefore, we demonstrated that GJB4 could regulate the Wnt/CTNNB1 signaling.




Figure 5 GJB4 knockdown inhibits self-renewal and tumor growth of GC cells.

Notes: (A, B) The effects of GJB4 on the colony formation in GJB4-knockdown HGC-27 and SGC-7901 cells. (C) Xenograft assays were performed after GJB4 knockdown in SGC-7901 cells. The size and weight of xenograft tumor were analyzed with 2-tailed Student t and P-value is indicated. (D) The growth curve of xenograft tumor was analyzed with 2-tailed Student t and P-value is indicated. (E) Immunoblotting of GJB4, CTNNB1, MYC, MMP7 and CCND1 in tumour samples. The GAPDH was used as a loading control. All data are shown as the means \pm SD, * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. All p-values are based on control versus treatment.

Abbreviations: GC, gastric cancer; GJB4, gap junction beta-4; MYC, MYC proto-oncogene; CCND1, G1/S-specific cyclin-D1; MMP7, matrix metalloproteinase-7; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Conclusion

In summary, our study indicates for the first time that GJB4 promotes cell proliferation and migration through the Wnt/CTNNB1 signaling in human GC cells. Our findings provide new insights into the function of GJB4 and indicate that GJB4 is a promising biomarker and therapeutic target for gastric cancer.

Acknowledgments

This work was supported by the Science and Technology Research Projects of Chongqing Education Commission (Grant No. KJQN201802704, KJQN1725391 and KJQN201802702), the Scientific Research Foundation of the Chongqing University of Arts and Sciences (2017ZBX10), and the Natural Science Research Projects of Chongqing Three Gorges Medical College (Grant No. 2016xmpxz04).

Disclosure

The authors report no conflicts of interest in this work.

References

- Kamangar F, Dores GM, Anderson WF, et al. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. *J Clin Oncol*. 2006;24(14):2137–2150.
- Kojima A, Shimada M, Mikami Y, et al. Chemoresistance of gastric-type mucinous carcinoma of the uterine cervix: a study of the sankai gynecology study group. *Int J Gynecol Cancer*. 2018;28(1):99–106. doi:10.1097/IGC.0000000000001145
- Chang P, Wang F, Li Y. Hsa_circ_0000673 is down-regulated in gastric cancer and inhibits the proliferation and invasion of tumor cells by targeting miR-532-5p. *Biosci Rep*. 2018;38(5):BSR20180538. doi:10.1042/BSR20180538
- Li JH, Shen WZ, Gu XQ, Hong W-K, Wang Z-Q. Prognostic value of EUS combined with MSCT in predicting the recurrence and metastasis of patients with gastric cancer. *Jpn J Clin Oncol*. 2017;47(6):487–493. doi:10.1093/jjco/hyx024
- Kim HJ, Oh SC. Novel systemic therapies for advanced gastric cancer. *J Gastric Cancer*. 2018;18(1):1–19. doi:10.5230/jgc.2018.18.e3
- el-Sabban ME, Pauli BU. Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium. *J Cell Biol*. 1991;115(5):1375–1382. doi:10.1083/jcb.115.5.1375
- Nicolson GL, Dulski KM, Trosko JE. Loss of intercellular junctional communication correlates with metastatic potential in mammary adenocarcinoma cells. *Proc Natl Acad Sci U S A*. 1988;85(2):473–476. doi:10.1073/pnas.85.2.473

8. Brauner T, Schmid A, Hulser DF. Tumor cell invasion and gap junctional communication. I. Normal and malignant cells confronted in monolayer cultures. *Invasion Metastasis*. 1990;10(1):18–30.
9. Krutovskikh VA, Troyanovsky SM, Piccoli C, Tsuda H, Asamoto M, Yamasaki H. Differential effect of subcellular localization of communication impairing gap junction protein connexin43 on tumor cell growth in vivo. *Oncogene*. 2000;19(4):505–513. doi:10.1038/sj.onc.1203340
10. Kanczuga-Koda L, Sulkowski S, Lenczewski A, et al. Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer. *J Clin Pathol*. 2006;59(4):429–433. doi:10.1136/jcp.2005.029272
11. Teleki I, Szasz AM, Maros ME, et al. Correlations of differentially expressed gap junction connexins Cx26, Cx30, Cx32, Cx43 and Cx46 with breast cancer progression and prognosis. *PLoS One*. 2014;9(11):e112541. doi:10.1371/journal.pone.0112541
12. Banerjee D. Connexin's connection in breast cancer growth and progression. *Int J Cell Biol*. 2016;2016:9025905. doi:10.1155/2016/9025905
13. Kotini M, Mayor R. Connexins in migration during development and cancer. *Dev Biol*. 2015;401(1):143–151. doi:10.1016/j.ydbio.2014.12.023
14. Gielen PR, Aftab Q, Ma N, et al. Connexin43 confers Temozolomide resistance in human glioma cells by modulating the mitochondrial apoptosis pathway. *Neuropharmacology*. 2013;75:539–548. doi:10.1016/j.neuropharm.2013.05.002
15. Kyo N, Yamamoto H, Takeda Y, et al. Overexpression of connexin 26 in carcinoma of the pancreas. *Oncol Rep*. 2008;19(3):627–631.
16. Murphy SF, Varghese RT, Lamouille S, et al. Connexin 43 inhibition sensitizes chemoresistant glioblastoma cells to temozolomide. *Cancer Res*. 2016;76(1):139–149. doi:10.1158/0008-5472.CAN-15-1286
17. Munoz JL, Rodriguez-Cruz V, Greco SJ, et al. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. *Cell Death Dis*. 2014;5:e1145. doi:10.1038/cddis.2014.111
18. Lin YP, Wu JI, Tseng CW, et al. Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation. *Oncogene*. 2019;38(6):822–837.
19. Wang F, Zhang D, Mao J, et al. Morusin inhibits cell proliferation and tumor growth by down-regulating c-Myc in human gastric cancer. *Oncotarget*. 2017;8(34):57187–57200. doi:10.18632/oncotarget.19231
20. Ouyang Y, Li Y, Huang Y, et al. CircRNA circPDSS1 promotes the gastric cancer progression by sponging miR-186-5p and modulating NEK2. *J Cell Physiol*. 2019;234(7):10458–10469.
21. Chen X, Li C, Cheng R, et al. miR-129-5p and -3p co-target WWP1 to suppress gastric cancer proliferation and migration. *J Cell Biochem*. 2019;120(5):7527–7538.
22. Shi P, Wan J, Song H, et al. The emerging role of circular RNAs in gastric cancer. *Am J Cancer Res*. 2018;8(10):1919–1932.
23. Chen J, Shin JH, Zhao R, et al. CSN6 drives carcinogenesis by positively regulating Myc stability. *Nat Commun*. 2014;5:5384. doi:10.1038/ncomms5972
24. Grek CL, Rhett JM, Bruce JS, Ghatnekar GS, Yeh ES. Connexin 43, breast cancer tumor suppressor: missed connections? *Cancer Lett*. 2016;374(1):117–126. doi:10.1016/j.canlet.2016.02.008
25. Kumar NM, Gilula NB. The gap junction communication channel. *Cell*. 1996;84(3):381–388. doi:10.1016/s0092-8674(00)81282-9
26. Xu N, Chen HJ, Chen SH, et al. Reduced Connexin 43 expression is associated with tumor malignant behaviors and biochemical recurrence-free survival of prostate cancer. *Oncotarget*. 2016;7(41):67476–67484. doi:10.18632/oncotarget.11231
27. McLachlan E, Shao Q, Laird DW. Connexins and gap junctions in mammary gland development and breast cancer progression. *J Membr Biol*. 2007;218(1–3):107–121. doi:10.1007/s00232-007-9052-x
28. El-Saghir JA, El-Habre ET, El-Sabban ME, Talhouk RS. Connexins: a junctional crossroad to breast cancer. *Int J Dev Biol*. 2011;55(7–9):773–780. doi:10.1387/ijdb.113372je
29. Carette D, Gilleron J, Chevallier D, Segretain D, Pointis G. Connexin a check-point component of cell apoptosis in normal and physiological conditions. *Biochimie*. 2014;101:1–9. doi:10.1016/j.biochi.2013.11.015
30. Xing Y, Xiao Y, Zeng F, et al. Altered expression of connexin-43 and impaired capacity of gap junctional intercellular communication in prostate cancer cells. *J Huazhong Univ Sci Technolog Med Sci*. 2007;27(3):291–294. doi:10.1007/s11596-007-0319-3

Supplementary materials




Figure S1 Kaplan-Meier overall survival for GJB4 expression in mixed types gastric cancer tumours (KM plotter gastric cancer dataset), and *P*-value is indicated.
Abbreviations: GC, gastric cancer; GJB4, gap junction beta-4.




Figure S2 (A, B) Representative immunofluorescent images of MKI67 assay for HGC-27 and SGC-7901 cell lines. **(C, D)** Representative immunofluorescent images of PCNA assay for HGC-27 and SGC-7901 cell lines. All data are shown as the means \pm SD, **p*<0.05, ***p*<0.01, ****p*<0.001. All *p*-values are based on control versus treatment.
Abbreviations: MKI67, marker of proliferation Ki-67; PCNA, proliferating cell nuclear antigen.




Figure S3 Cell migration of indicated stable cell lines was measured by Transwell assay. All data are shown as the means \pm SD, * p <0.05, ** p <0.01, *** p <0.001. All p -values are based on control versus treatment.

Abbreviation: GJB4, Gap junction beta-4.

OncoTargets and Therapy

Dovepress

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>